Washington, Mar 3 : In an international trial conducted in eight countries, including India, has shown that using biphasic BIAsp 30 insulin can lead to significant clinical improvements and greater patient satisfaction.
The study conducted on 52,000 patients found that 53 per cent achieved a blood glucose (HbA1c) level of less than seven per cent, which was equivalent to the target set by the International Diabetes Foundation.
The IMPROVE study was based on the largest database of Type II Diabetes patients ever compiled, and in the first phase it covered eight countries: Canada, China, Greece, India, Italy, Japan, Poland and Russia.